Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Cancer Research




Integrated Solutions for Cancer Research

Innovation to Meet the Needs of Evolving Cancer Hallmarks

Your aim may be to investigate cancer’s genetic origins, establish the mechanism of action or clinical implications of tumor biomarkers, or develop a targeted pharmaceutical or cellular therapy. At Enzo, our aim is to support yours. As cancer hallmarks have evolved over the last decade, so has our portfolio of tools to support cancer research. Over this time, we have called upon our diverse scientific and technical expertise to create innovative assays and reagents in the fields of epigenetics, autophagy, and Wnt research. These novel tools, and a broad portfolio of products established for decades in peer-reviewed literature, will help support cancer discovery into the next decade, and beyond. We are continually focused on enabling a future with more hope, more collaboration, more discovery, and less disease.

 

Discover the next cancer breakthrough…

  • Modulate with high-purity small molecules & active proteins
  • Label with proprietary DNA & RNA amplification & labeling technologies
  • Detect with sensitive, widely-published biomarker ELISAs, antibodies & cell-based assays
 

Metabolism
Monitor Adipokine &
Insulin Signaling

Oxidative Stress & DNA Damage
Quantify Critical Markers of Cellular Stress

Programmed Cell Death
Monitor Cell Fate & Quantify
Mediators of Death Pathways

Tumor Immunology
Define Innate & Adaptive
Anti-tumor Responses

Tumor Invasion & Angiogenesis
Detect and Screen Key Biomarkers of
Metastatic Potential

Oncogenic Signaling
Monitor Pro-growth Signals from Cell
Surface to Nucleus

Toxicity & Chemoresistance
Characterize Novel &
Repurposed Therapeutics

Gene Expression & Copy Number
Reveal Genomic Changes with High-fidelity
Nucleic Acid Labeling

Epigenetic Regulation
Flexible Formats for HDAC
& Sirtuin Screening

Tumor Immunology
CD40, TRAIL, and FasL Mega™ Ligands
CRP ELISA
TNF Superfamily Antibodies & Proteins
PGE2, TXB2, LTB4 & COX ELISA Kits
Human & Mouse Cytokine ELISA Kits
TLR Signaling Antibodies & Ligands
NF-kB p65 ELISA Kit

Tumor Invasion & Angiogenesis
MMP Red & Green Fluorometric Drug Discovery Kits
VEGF & VEGFR Detection & Inhibition
HIF-1&alpha: and HIF-2&alpha: Antibodies & Modulators
Serine Protease ELISAs & Antibodies
NGAL ELISA Kits

Wnt Pathway Analysis
Leading Light™ Wnt Reporter Assay
Dkk-1, GSK-3β, & β-catenin ELISA Kits
Wnt Compound Library

Cell Cycle Analysis
Nuclear-ID® Cell Viability Reagents
Nuclear-ID® Cell Cycle Analysis Kits
Nucleolar-ID® Detection Kits
CDK Inhibitors & Cyclin Antibodies
p21 & p27Kip1 ELISAs
Kinase Inhibitor Library

 

Serine Proteases and Cancer

Novel Serine Protease Cancer Biomarker Products

Enzo Life Sciences offers more than 40 unique serine protease related products specifically related to cancer biomarker discovery, with emphasis on key family members identified as markers of early stage ovarian, breast, prostate and lung cancer.

  • High-sensitivity, easy-to use and rapid ELISA kits
  • Ready-to-user proteins for use as ELISA or Western blot standards
  • Exclusive antibodies created against native proteins

 

Related Documents

Latest Literature

Product Flyers
Cancer Research Products
Cancer Research Products 17-May-13
Download as PDF

upcoming Webinar

Inhibition of Hypoxia Using a 3D Cell Culture Model

Date: Wednesday, November 19, 2014
Time: Noon - 1 PM EST


Topics include:

  • Overview of hypoxia and the use of spheroids as a model of avascular tumors with hypoxic cores
  • Importance of co-cultures
  • Explanation of mechanism of action of the detection reagents
  • Protocol optimization
  • Analysis of hypoxia inhibition
  • Conclusion
  • Q&A
Presenters:
  • Nicky Slawny, Ph.D., Applications Director, 3D Biomatrix, Inc.
  • Brad Larson, Principal Scientist, BioTek Instruments, Inc.
  • Wini Luty, Product Manager, Enzo Life Sciences, Inc.

 

Recommend this page

 
Keep in touch

©2014 Enzo Life Sciences, Inc.,